ArticleThe Journal of international medical research2021
Nomogram based on immune scores for predicting the survival of patients with esophageal squamous cell carcinoma.
Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- AI in esophageal cancer: advances, barriers to clinical translation, and perspectives for digital health.Journal of translational medicine · 2026Review
- Decoding osteosarcoma from heterogeneity to precision therapy.Discover oncology · 2025Review
- A novel staging system based on deep learning for overall survival in patients with esophageal squamous cell carcinoma.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the relationship between immune scores and prognosis of patients with esophageal squamous cell carcinoma (ESCC) and construct a corresponding clinical prediction model.
methodsThe present research was a retrospective cohort study. We obtained the clinical information and immune scores of 137 patients with ESCC from The Cancer Genome Atlas database, and a Cox proportional risk model was used to construct the clinical prediction model. The concordance index, receiver operating characteristic curve, calibration curve, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate model performance and prediction accuracy.
resultsPatients with a high immune score (> -121.4) showed a worse prognosis than those with a low immune score (< -645.8; hazard ratio=3.743, 95% confidence interval [CI]=1.385-10.115, P=0.009). The concordance index of the predictive model was 0.733 (95% CI=0.655-0.812). The calibration curve showed that the 3- and 5-year overall survival rates predicted by the model were highly consistent with the observed values. The NRI and IDI for the 3-year overall survival indicated that the model with the immune scores was superior for classifying the risk probability and distinguishing cases.
conclusionImmune scores may be an independent predictor of prognosis in patients with ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.